VEGFA and neoplasm: Mechanistically, sorafenib blocks vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptors to suppress tumour angiogenesis or inhibit MAP Kinase pathways to suppress tumour cell proliferation45,46.